Mexdagry

Metformin Hydrochloride and Dapagliflozin, the active ingredients in Mexdagry, are a biguanide and SGLT2 inhibitor presented as tablets for oral use. They are indicated for the management of type 2 diabetes mellitus in adults, used alongside diet, exercise and lifestyle modifications to achieve optimal glycemic control.

GNH USA supplies Mexdagry as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide through a robust quality‑assured distribution network that meets global regulatory standards, ensuring timely delivery to end‑users.

Mexdagry combines metformin and dapagliflozin to target hyperglycemia in type 2 diabetes mellitus. - Initial therapy in type 2 diabetes mellitus: improves glycemic control as part of first‑line treatment together with diet and exercise. - Add‑on therapy for type 2 diabetes mellitus: provides additional glucose lowering when metformin alone does not achieve target HbA1c. - Combination therapy with other antidiabetic agents: can be used alongside insulin or other oral agents to further reduce blood glucose levels.

Common adverse reactions and rare serious events have been reported with the metformin/dapagliflozin combination.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Genital mycotic infection: increased risk of yeast infections in both sexes. - Urinary tract infection: symptoms such as dysuria or increased frequency. - Increased urinary volume: polyuria leading to mild dehydration.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Ketoacidosis: euglycemic diabetic ketoacidosis may occur. - Severe dehydration or hypotension: especially in patients with renal impairment. - Hypoglycemia: particularly when combined with insulin or sulfonylureas.

Before initiating Mexdagry, clinicians should evaluate several safety considerations. - Renal function assessment: confirm eGFR meets the minimum requirement for both components. - Lactic acidosis risk: avoid in patients with hepatic impairment, alcohol abuse, or conditions predisposing to hypoxia. - Hypoglycemia monitoring: adjust doses of concomitant insulin or sulfonylureas to prevent low blood glucose. - Genital infection vigilance: advise patients on proper genital hygiene to reduce infection risk. - Pregnancy and lactation: use only if potential benefits justify potential risks to the fetus or infant. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Mexdagry may interact with other medicines, altering efficacy or safety.

Major Interactions (Avoid): - Insulin or sulfonylureas: increased risk of hypoglycemia. - IV contrast agents: may precipitate acute kidney injury; consider temporary discontinuation of metformin. - Cimetidine: can raise dapagliflozin plasma concentrations. - Diuretics: may exacerbate dehydration and hypotension.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor renal function and electrolytes. - NSAIDs: may affect renal clearance and increase risk of kidney injury. - Alcohol: can potentiate metformin‑associated lactic acidosis.